论文信息 - Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531 - 字舞流文

Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531

S. Raimondi | S. Meshinchi | T. Alonzo | R. Gerbing | B. Hirsch | S. Davies | R. Aplenc | L. Sung | L. Winter | F. Smith | S. Kahwash | A. Gamis | Kathleen Glick | L. Burden | Patti Byron | Amy E Heerema-McKenney | Tanya Wallas | Laura Burden